About E3 ubiquitin-protein ligase TRIM21
E3 ubiquitin-protein ligase TRIM21 (TRIM21) is a protein
from Homo sapiens identified by UniProt accession
P19474, 475 residues long.
MolForge cross-references it against 0 known binders and
455 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM21 |
| UniProt accession | P19474 |
| Gene | TRIM21 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (455)
Diseases linked to this target (Open Targets).
- lung adenocarcinoma · score 0.23
- ovarian cancer · score 0.21
- glioblastoma multiforme · score 0.19
- clear cell renal carcinoma · score 0.19
- squamous cell lung carcinoma · score 0.14
- head and neck squamous cell carcinoma · score 0.14
- Systemic lupus erythematosus · score 0.12
- systemic scleroderma · score 0.11
- neoplasm · score 0.11
- interstitial lung disease · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P19474-F1 | alphafold | PREDICTED | 90.66 | — |
Amino-acid sequence (475 residues)
MASAARLTMM WEEVTCPICL DPFVEPVSIE CGHSFCQECI SQVGKGGGSV CPVCRQRFLL KNLRPNRQLA NMVNNLKEIS QEAREGTQGE RCAVHGERLH LFCEKDGKAL CWVCAQSRKH RDHAMVPLEE AAQEYQEKLQ VALGELRRKQ ELAEKLEVEI AIKRADWKKT VETQKSRIHA EFVQQKNFLV EEEQRQLQEL EKDEREQLRI LGEKEAKLAQ QSQALQELIS ELDRRCHSSA LELLQEVIIV LERSESWNLK DLDITSPELR SVCHVPGLKK MLRTCAVHIT LDPDTANPWL ILSEDRRQVR LGDTQQSIPG NEERFDSYPM VLGAQHFHSG KHYWEVDVTG KEAWDLGVCR DSVRRKGHFL LSSKSGFWTI WLWNKQKYEA GTYPQTPLHL QVPPCQVGIF LDYEAGMVSF YNITDHGSLI YSFSECAFTG PLRPFFSPGF NDGGKNTAPL TLCPLNIGSQ GSTDY
Explore E3 ubiquitin-protein ligase TRIM21 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets